Bristol-Myers Squibb has announced the completion of the $2.4bn acquisition of Medarex, a leader in immune disease and cancer treatments. As a result of the transaction Medarex has now become a wholly...
* Bristol to pay 90 pct premium for Medarex shares * Deal would give Bristol full ownership of melanoma drug * Bristol sees deal enhancing cancer, immunology strength (Adds quotes on terms, significance of deal,...
NEW YORK, July 22 - U.S. drugmaker Bristol-Myers Squibb Co late on Wednesday said it will pay $2.4 billion to acquire Medarex Inc, a biotechnology company that has been helping it develop a promising treatment...
NEW YORK, July 22 - U.S. drugmaker Bristol-Myers Squibb Co late on Wednesday said it will pay $2.4 billion to acquire Medarex Inc, a biotechnology company that is developing treatments for cancer and other diseases....
* Bristol-Myers to buy biotech company Medarex Inc * 3M raises 2009 revenue forecast * Data on tap includes weekly jobless claims NEW YORK, July 23 - U.S. stock index futures rose on Thursday as...
* Bristol-Myers to buy biotech company Medarex Inc * Data on tap includes weekly jobless claims NEW YORK, July 23 - U.S. stock index futures rose slightly on Thursday as investors remained positive following an...